Q1 Earnings Estimate for MMSI Issued By Barrington Research

Merit Medical Systems, Inc. (NASDAQ:MMSI) – Equities research analysts at Barrington Research reduced their Q1 2025 EPS estimates for shares of Merit Medical Systems in a research note issued to investors on Wednesday, February 26th. Barrington Research analyst M. Petusky now expects that the medical instruments supplier will post earnings of $0.76 per share for the quarter, down from their previous estimate of $0.88. Barrington Research currently has a “Outperform” rating and a $111.00 target price on the stock. The consensus estimate for Merit Medical Systems’ current full-year earnings is $3.37 per share. Barrington Research also issued estimates for Merit Medical Systems’ Q2 2025 earnings at $1.03 EPS, Q4 2025 earnings at $0.98 EPS, Q1 2026 earnings at $0.86 EPS, Q2 2026 earnings at $1.12 EPS, Q3 2026 earnings at $0.98 EPS, Q4 2026 earnings at $1.04 EPS and FY2027 earnings at $4.35 EPS.

A number of other equities research analysts also recently weighed in on MMSI. Wells Fargo & Company decreased their price target on shares of Merit Medical Systems from $120.00 to $117.00 and set an “overweight” rating on the stock in a research note on Wednesday. Needham & Company LLC decreased their price target on Merit Medical Systems from $122.00 to $116.00 and set a “buy” rating on the stock in a research report on Wednesday. StockNews.com cut shares of Merit Medical Systems from a “buy” rating to a “hold” rating in a research report on Sunday, November 3rd. Canaccord Genuity Group dropped their target price on Merit Medical Systems from $128.00 to $127.00 and set a “buy” rating for the company in a research report on Wednesday. Finally, Piper Sandler restated an “overweight” rating and issued a $116.00 price objective (up from $114.00) on shares of Merit Medical Systems in a report on Wednesday, January 29th. Two analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $110.78.

Merit Medical Systems Price Performance

Shares of MMSI stock opened at $102.04 on Friday. Merit Medical Systems has a 12 month low of $70.70 and a 12 month high of $111.45. The company has a market capitalization of $5.95 billion, a P/E ratio of 50.02, a P/E/G ratio of 2.34 and a beta of 0.87. The stock has a 50 day moving average of $102.91 and a two-hundred day moving average of $99.96. The company has a current ratio of 5.36, a quick ratio of 3.82 and a debt-to-equity ratio of 0.57.

Institutional Trading of Merit Medical Systems

Hedge funds have recently bought and sold shares of the stock. Barclays PLC grew its holdings in shares of Merit Medical Systems by 305.4% during the third quarter. Barclays PLC now owns 112,727 shares of the medical instruments supplier’s stock worth $11,142,000 after buying an additional 84,923 shares in the last quarter. EULAV Asset Management raised its stake in Merit Medical Systems by 400.0% in the 4th quarter. EULAV Asset Management now owns 115,000 shares of the medical instruments supplier’s stock valued at $11,123,000 after acquiring an additional 92,000 shares during the period. Van ECK Associates Corp bought a new position in shares of Merit Medical Systems in the third quarter valued at about $718,000. Fisher Asset Management LLC lifted its position in Merit Medical Systems by 3.2% during the third quarter. Fisher Asset Management LLC now owns 221,690 shares of the medical instruments supplier’s stock worth $21,910,000 after acquiring an additional 6,837 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in Merit Medical Systems by 85.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 575,946 shares of the medical instruments supplier’s stock valued at $56,921,000 after purchasing an additional 265,648 shares during the period. 99.66% of the stock is currently owned by institutional investors and hedge funds.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.